Eli Lilly released top-line data from TRIUMPH-1 on May 21, 2026 — the pivotal Phase 3 obesity trial that will anchor retatrutide's New Drug Application. The headline: 30.3% average body weight loss at 104 weeks in participants with a baseline BMI of 35 or higher. That number crosses into territory historically associated with bariatric surgery.
Research-context information only. Retatrutide is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
The TRIUMPH-1 Numbers
TRIUMPH-1 enrolled 2,339 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) plus at least one weight-related comorbidity, without type 2 diabetes. The trial randomized participants across three retatrutide doses (4 mg, 9 mg, 12 mg) versus placebo, all administered once weekly by subcutaneous injection.
80-week efficacy (primary endpoint):
| Dose | Mean Weight Loss | Mean Pounds Lost | Achieved 30%+ Loss |
|---|---|---|---|
| 12 mg | 28.3% | 70.3 lbs | 45.3% |
| 9 mg | 25.9% | — | — |
| 4 mg | 19.0% | 47.2 lbs | — |
| Placebo | 2.2% | — | — |
All three doses met the primary and key secondary endpoints.
104-week extension: A prespecified blinded extension enrolled 532 participants with baseline BMI of 35 or higher. At 104 weeks, the 12 mg arm achieved 30.3% average weight loss — approximately 85.0 lbs. This confirms that retatrutide's weight-loss trajectory had not plateaued at 80 weeks, unlike semaglutide and tirzepatide trials where the curve flattens between weeks 60 and 72.
The 4 mg dose deserves attention: 19.0% weight loss at 80 weeks with a discontinuation rate (4.1%) lower than placebo (4.9%). That gives Lilly a low-dose maintenance option that competitors do not currently offer.
Where Retatrutide Now Sits vs the Competition
Cross-trial comparisons have limitations, but the magnitude gaps are large enough to draw conclusions:
| Compound | Trial | Duration | Max Weight Loss | Mechanism |
|---|---|---|---|---|
| Retatrutide 12 mg | TRIUMPH-1 | 80 wk | 28.3% | GIP + GLP-1 + glucagon |
| Tirzepatide 15 mg | SURMOUNT-1 | 72 wk | 22.5% | GIP + GLP-1 |
| CagriSema | REDEFINE-2 | 68 wk | 22.7% | Amylin + GLP-1 |
| Semaglutide 2.4 mg | STEP-1 | 68 wk | 14.9% | GLP-1 |
| Survodutide | SYNCHRONIZE-1 | 48 wk | 16.6% | GLP-1 + glucagon |
Retatrutide at 12 mg produces the largest weight loss of any published Phase 3 GLP-1-class compound. The added glucagon-receptor agonism appears to be the differentiator — it drives energy expenditure in a way that dual agonists do not.
The 104-week extension data (30.3%) is particularly significant. No competing compound has published Phase 3 data showing weight loss continuing to deepen past 80 weeks. This sustained trajectory could reshape formulary positioning if the safety profile holds.
Safety Profile
The adverse event pattern was consistent with the incretin class. Most common events were gastrointestinal: nausea, diarrhea, constipation, and vomiting, generally mild to moderate in severity.
Discontinuation rates due to adverse events:
| Dose | Discontinuation Rate |
|---|---|
| 4 mg | 4.1% |
| 9 mg | 6.9% |
| 12 mg | 11.3% |
| Placebo | 4.9% |
Dysesthesia — the abnormal tingling sensation first flagged in TRIUMPH-4 — was reported in TRIUMPH-1 as well, though Lilly's top-line release described it as generally mild with most affected participants continuing treatment. The 80-week duration provides the longest follow-up on this signal to date. We covered the dysesthesia mechanism and management in the retatrutide dysesthesia side-effect breakdown.
At 65.3% of the 12 mg arm reaching BMI below 30 by week 80, the metabolic normalization rate is the highest reported in any obesity pharmacotherapy trial.
What This Means for the NDA and Timeline
TRIUMPH-1 was the final missing piece for Lilly's obesity filing. The updated regulatory timeline:
- May 21, 2026: TRIUMPH-1 top-line data released
- June 2026: Detailed data presented at the 86th ADA Scientific Sessions
- Q4 2026: NDA submission to FDA (obesity indication)
- 2027: FDA review period (6-10 months standard; potentially accelerated via National Priority Voucher)
If Lilly uses the Commissioner's National Priority Voucher — the same mechanism that compressed orforglipron's review to roughly 50 days — retatrutide approval could arrive as early as Q1 2027. Without the voucher, mid-to-late 2027 is the realistic timeline.
The remaining TRIUMPH trials (TRIUMPH-2 in obesity + T2D, TRIUMPH-3 in cardiovascular disease, TRIUMPH-OSA in sleep apnea, TRIUMPH-5 in liver disease, TRIUMPH-6 in chronic low back pain) will expand the label but are not required for the initial obesity approval.
